Javascript must be enabled for this website to work.

#script { display:none; } #noScript{ width: 350px; height: 175px; text-align: center; background: white; padding: 35px; display: block; margin-top: -87px; top: 50%; position: absolute; border-bottom: 1px solid #c2c2c2; border-left: 1px solid #e6e6e6; border-right: 1px solid #e6e6e6; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; margin-left: 50%; left: -175px; } #noScript img{width:100%;} body{background:#f7f7f7;}

gastroenterology

IBD

Introduction of sub-cutaneous infliximab (Remsima SC) expands treatment options for patients

9 Dec 2020

Sponsored by Celltrion Healthcare Australia Pty Ltd

The recent TGA approval of subcutaneous (SC) infliximab (Remsima SC) across all current infliximab indications expands the treatment options for adult patients with chronic inflammatory diseases, including inflammatory bowel disease. The SC formulation was approved by the TGA in on 12th November 2020. The manufacturer, Celltrion, has applied for reimbursement, with hopes of PBS availability ...

Already a member?

Forgot my password

Not a member yet?

Join now for free, independent news relevant to your specialty. the limbic is intended for practicing health care professionals only.

Title: *

First name: *

Last name: *

Country: *

Email: *

Password: *

Password must contain at least 8 characters including 1 letter and 1 number.

AHPRA Number: * Find my AHPRA number

What's your primary area of interest? *

The limbic's weekly newsletter is a round up of key news highlights that's relevant to your specialty. The newsletter may contain advertising and educational or promotional material from carefully selected industry partners including pharmaceutical companies, government and not-for-profit organisations.

You will not receive advertisers only emails and your details will not be shared with any other party.

I would like to receive the limbic newsletter *

I have read and agree to the limbic Terms and Conditions & Privacy Policy *

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cancel